Loading...

CALC CALCIMEDICA INC Operational Disruptions 8-K Filing

CLCM

CLC

CALCIMEDICA INC

(CALC)

2024 8-K

NASDAQ Compliance Issues

Financial Results Announcement

Trial Discontinued

Trial Discontinuation

Quarterly Financial Results

Stock Offering Update

Equity Offerings

Financial Statements

Financial Results

Clinical Trial Results

Stock Offering Update

Financial Results

Management Change

Financial Update

Positive Trial Results

Equity Plan Update

Financial Results

Phase 2b CARPO Trial Toplin...

Financial Results Announcement

Dismissal of Independent Re...

Increase in Offering Price

Financial Results Announcement

Regulation FD Disclosure an...

Amendment to Private Placement

Private Placement

Financial Results Announcement

Financial Condition and Oth...

Updated Business Description

Financial Results and Annua...

Annual Meeting Date Set

Regulation FD Disclosure

Earnings Reports

Restatement of Financial St...

Merger of Equals

Termination of Employment

Director Appointments and R...

External Links:

Calcimedica, Inc. announced positive topline data from the Phase 2b CARPO trial of Auxora in acute pancreatitis, showing a dose response for time to solid food tolerance and reduction of severe organ failure.

AI Assistant

CALCIMEDICA INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.